Decibel Therapeutics (DBTX) Appoints Kevin F. McLaughlin to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors
October 12, 2022 7:00 AM EDTBOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Kevin F. McLaughlin to its Board of Directors.
We are pleased to welcome Kevin to the Decibel Board. He brings a wealth of biopharma experience, including guiding biotech companies through stages of increasing financial and operational maturity, said Laurence Reid, Ph.D., Chief Executive Officer at Decibel. His appointment to the Board provides us with a critical strategic... More
